

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
June 04, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

June 4 2007

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b): 82-\_\_\_\_\_

MISCELLANEOUS

TOTAL NUMBER OF VOTING RIGHTS AND SIZE OF SHARE CAPITAL IN NOVO NORDISK A/S AS  
OF 1 JUNE 2007

Edgar Filing: NOVO NORDISK A S - Form 6-K

In accordance with Section 17(2) of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required on 1 June 2007 to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S.

Please find below a statement regarding the total number of voting rights and size of share capital in Novo Nordisk A/S as of 1 June 2007.

|          | NUMBER OF SHARES (NOMINAL VALUE DKK 2) | NOMINAL VALUE (DKK) | NUMBER |
|----------|--|---------------------|--------|
| A SHARES | 53,743,600                             | 107,487,200         | 1,07   |
| B SHARES | 283,216,400                            | 566,432,800         | 56     |

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

For further information please contact:

|  |  |
|--|--|
| Media:   | Investors:   |
| Outside North America:   | Outside North America:   |
| Elin K Hansen  | Mads Veggerby Lausten  |
| Tel: (+45) 4442 3450   | Tel: (+45) 4443 7919   |
| <a href="mailto:ekh@novonordisk.com">ekh@novonordisk.com</a>   | <a href="mailto:mlau@novonordisk.com">mlau@novonordisk.com</a>   |
| -----  | -----  |
|  | Hans Rommer  |
|  | Tel: (+45) 4442 4765   |
|  | <a href="mailto:hrrmm@novonordisk.com">hrrmm@novonordisk.com</a> |
| In North America:  | In North America:  |
| Lori Moore   | Christian Qvist Frandsen   |
| Tel: (+1) 609 919 7991   | Tel: (+1) 609 919 7937   |
| <a href="mailto:lrmo@novonordisk.com">lrmo@novonordisk.com</a> | <a href="mailto:cqfr@novonordisk.com">cqfr@novonordisk.com</a>   |

Stock Exchange Announcement no 15/2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Date: June 4 2007

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer